SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer's disease

Jin Hongo, Shutaro Nakaaki, Yoshihiro Shinagawa, Yoshie Murata, Junko Sato, Hiroshi Tatsumi, Junko Tohyama, Tsutomu Soma, Tetsuya Iidaka, Toshiya Fukui, Masaru Mimura, Toshiaki A. Furukawa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background/Objective: We attempted to determine whether the pretreatment regional cerebral blood flow (rCBF) might predict cognitive changes in response to donepezil treatment, as assessed in terms of the Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog), and in relation to the severity of subcortical hyperintensities (SH). Method: Forty-one patients with Alzheimer's disease (AD) were treated with donepezil at baseline. All the patients underwent a single photon emission computed tomography examination before donepezil therapy. They also completed the ADAS-cog at baseline and after 24 weeks of donepezil therapy. SH were assessed semiquantitatively using a recently developed visual rating scale. We analyzed the correlation between the baseline rCBF and changes in the ADAS-cog score using statistical parametric mapping, including the severity of the SH as a covariate. Results: Lower pretreatment rCBF levels in the right orbitofrontal cortex (OFC) predicted a better improvement in the ADAS-cog score in response to donepezil therapy. The severity of SH did not appear to influence this correlation. Conclusions: This effect may reflect the choline acetyltransferase activity associated with the OFC. The presence of SH did not appear to influence the effect of donepezil therapy on the cognitive function as assessed by ADAS-cog.

Original languageEnglish
Pages (from-to)556-566
Number of pages11
JournalDementia and Geriatric Cognitive Disorders
Volume26
Issue number6
DOIs
Publication statusPublished - 2008 Dec
Externally publishedYes

Fingerprint

Single-Photon Emission-Computed Tomography
Cerebrovascular Circulation
Alzheimer Disease
Regional Blood Flow
Prefrontal Cortex
Therapeutics
Choline O-Acetyltransferase
Cognition
donepezil

Keywords

  • Alzheimer Disease Assessment Scale, cognitive subscale
  • Alzheimer's disease
  • Donepezil
  • Regional cerebral blood flow
  • Single photon emission computed tomography
  • Subcortical hyperintensities

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Cognitive Neuroscience

Cite this

SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer's disease. / Hongo, Jin; Nakaaki, Shutaro; Shinagawa, Yoshihiro; Murata, Yoshie; Sato, Junko; Tatsumi, Hiroshi; Tohyama, Junko; Soma, Tsutomu; Iidaka, Tetsuya; Fukui, Toshiya; Mimura, Masaru; Furukawa, Toshiaki A.

In: Dementia and Geriatric Cognitive Disorders, Vol. 26, No. 6, 12.2008, p. 556-566.

Research output: Contribution to journalArticle

Hongo, J, Nakaaki, S, Shinagawa, Y, Murata, Y, Sato, J, Tatsumi, H, Tohyama, J, Soma, T, Iidaka, T, Fukui, T, Mimura, M & Furukawa, TA 2008, 'SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer's disease', Dementia and Geriatric Cognitive Disorders, vol. 26, no. 6, pp. 556-566. https://doi.org/10.1159/000181148
Hongo, Jin ; Nakaaki, Shutaro ; Shinagawa, Yoshihiro ; Murata, Yoshie ; Sato, Junko ; Tatsumi, Hiroshi ; Tohyama, Junko ; Soma, Tsutomu ; Iidaka, Tetsuya ; Fukui, Toshiya ; Mimura, Masaru ; Furukawa, Toshiaki A. / SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer's disease. In: Dementia and Geriatric Cognitive Disorders. 2008 ; Vol. 26, No. 6. pp. 556-566.
@article{84c4199e1fd04abd82409b34d6247c9f,
title = "SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer's disease",
abstract = "Background/Objective: We attempted to determine whether the pretreatment regional cerebral blood flow (rCBF) might predict cognitive changes in response to donepezil treatment, as assessed in terms of the Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog), and in relation to the severity of subcortical hyperintensities (SH). Method: Forty-one patients with Alzheimer's disease (AD) were treated with donepezil at baseline. All the patients underwent a single photon emission computed tomography examination before donepezil therapy. They also completed the ADAS-cog at baseline and after 24 weeks of donepezil therapy. SH were assessed semiquantitatively using a recently developed visual rating scale. We analyzed the correlation between the baseline rCBF and changes in the ADAS-cog score using statistical parametric mapping, including the severity of the SH as a covariate. Results: Lower pretreatment rCBF levels in the right orbitofrontal cortex (OFC) predicted a better improvement in the ADAS-cog score in response to donepezil therapy. The severity of SH did not appear to influence this correlation. Conclusions: This effect may reflect the choline acetyltransferase activity associated with the OFC. The presence of SH did not appear to influence the effect of donepezil therapy on the cognitive function as assessed by ADAS-cog.",
keywords = "Alzheimer Disease Assessment Scale, cognitive subscale, Alzheimer's disease, Donepezil, Regional cerebral blood flow, Single photon emission computed tomography, Subcortical hyperintensities",
author = "Jin Hongo and Shutaro Nakaaki and Yoshihiro Shinagawa and Yoshie Murata and Junko Sato and Hiroshi Tatsumi and Junko Tohyama and Tsutomu Soma and Tetsuya Iidaka and Toshiya Fukui and Masaru Mimura and Furukawa, {Toshiaki A.}",
year = "2008",
month = "12",
doi = "10.1159/000181148",
language = "English",
volume = "26",
pages = "556--566",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer's disease

AU - Hongo, Jin

AU - Nakaaki, Shutaro

AU - Shinagawa, Yoshihiro

AU - Murata, Yoshie

AU - Sato, Junko

AU - Tatsumi, Hiroshi

AU - Tohyama, Junko

AU - Soma, Tsutomu

AU - Iidaka, Tetsuya

AU - Fukui, Toshiya

AU - Mimura, Masaru

AU - Furukawa, Toshiaki A.

PY - 2008/12

Y1 - 2008/12

N2 - Background/Objective: We attempted to determine whether the pretreatment regional cerebral blood flow (rCBF) might predict cognitive changes in response to donepezil treatment, as assessed in terms of the Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog), and in relation to the severity of subcortical hyperintensities (SH). Method: Forty-one patients with Alzheimer's disease (AD) were treated with donepezil at baseline. All the patients underwent a single photon emission computed tomography examination before donepezil therapy. They also completed the ADAS-cog at baseline and after 24 weeks of donepezil therapy. SH were assessed semiquantitatively using a recently developed visual rating scale. We analyzed the correlation between the baseline rCBF and changes in the ADAS-cog score using statistical parametric mapping, including the severity of the SH as a covariate. Results: Lower pretreatment rCBF levels in the right orbitofrontal cortex (OFC) predicted a better improvement in the ADAS-cog score in response to donepezil therapy. The severity of SH did not appear to influence this correlation. Conclusions: This effect may reflect the choline acetyltransferase activity associated with the OFC. The presence of SH did not appear to influence the effect of donepezil therapy on the cognitive function as assessed by ADAS-cog.

AB - Background/Objective: We attempted to determine whether the pretreatment regional cerebral blood flow (rCBF) might predict cognitive changes in response to donepezil treatment, as assessed in terms of the Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog), and in relation to the severity of subcortical hyperintensities (SH). Method: Forty-one patients with Alzheimer's disease (AD) were treated with donepezil at baseline. All the patients underwent a single photon emission computed tomography examination before donepezil therapy. They also completed the ADAS-cog at baseline and after 24 weeks of donepezil therapy. SH were assessed semiquantitatively using a recently developed visual rating scale. We analyzed the correlation between the baseline rCBF and changes in the ADAS-cog score using statistical parametric mapping, including the severity of the SH as a covariate. Results: Lower pretreatment rCBF levels in the right orbitofrontal cortex (OFC) predicted a better improvement in the ADAS-cog score in response to donepezil therapy. The severity of SH did not appear to influence this correlation. Conclusions: This effect may reflect the choline acetyltransferase activity associated with the OFC. The presence of SH did not appear to influence the effect of donepezil therapy on the cognitive function as assessed by ADAS-cog.

KW - Alzheimer Disease Assessment Scale, cognitive subscale

KW - Alzheimer's disease

KW - Donepezil

KW - Regional cerebral blood flow

KW - Single photon emission computed tomography

KW - Subcortical hyperintensities

UR - http://www.scopus.com/inward/record.url?scp=57249088716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57249088716&partnerID=8YFLogxK

U2 - 10.1159/000181148

DO - 10.1159/000181148

M3 - Article

VL - 26

SP - 556

EP - 566

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 6

ER -